跳到正文
原文
MedTech Dive 器械媒体· Elise Reuter·· 2026-10-13AI 评分51

Ascensia领投CGM初创公司Sava Technologies 3600万美元B轮融资

Ascensia leads $36M funding round for glucose sensor startup

AI 导读

Ascensia Diabetes Care领投伦敦葡萄糖传感器初创公司Sava Technologies 3600万美元B轮融资,并达成战略合作,获得其传感器在欧洲的独家商业化与分销权。Sava计划用这笔资金扩大生产并准备推出首款产品,其微传感器长度约为现有主流器件的十分之一,公司计划今年启动关键性试验,目标两年内获得CE标志后在欧洲上市。

正文

An article from site logo

Dive Brief

Ascensia also struck an exclusive sales agreement with Sava, which is making a wearable to continuously monitor glucose and other biomarkers.

Published Oct. 12, 2026

Elise Reuter's headshot

A person wears a white, oval device on their upper arm while their hair blows in the wind.

Sava Technologies raised $36 million in funding to develop a wearable glucose sensor that could expand to other biomarkers. Permission granted by Sava Technologies

Dive Brief:

  • Ascensia Diabetes Care led a $36 million Series B round in London-based glucose sensor maker Sava Technologies, the startup said Friday.
  • The companies also struck a strategic partnership that gives Ascensia exclusive commercialization and distribution rights, starting in Europe. Based in Basel, Switzerland, Ascensia is a subsidiary of Tokyo’s PHC Holdings.
  • Sava is developing a wearable glucose sensor that could expand to other biomarkers in the future. Sava hopes for the device to provide more options for people who use continuous glucose monitors in a market currently dominated by Abbott and Dexcom.

Dive Insight:

Sava plans to use the funds to scale up manufacturing and prepare to sell its first product. 

The company is developing a continuous glucose sensor that, like other CGMs, measures glucose in the interstitial fluid just beneath the skin. However, Sava claims its microsensors are about 10 times shorter than the filament used in most devices today, reducing disruption to the skin.

The company plans to start a pivotal trial this year, with the goal of launching the device in Europe after receiving a CE mark in the next two years. Sava intends for its sensor to be approved for non-adjunctive use, meaning it could be used for insulin dosing decisions without routine fingersticks to confirm. 

Ascensia plans to start distributing Sava’s sensor in Europe. Ascensia, which makes diabetes supplies including blood glucose meters, test strips and lancets, said it has made a strategic equity investment in Sava, and that its microsensor technology has potential in the long term for health monitoring beyond glucose. 

Ascensia previously struck a distribution agreement with another CGM maker, Senseonics, whose sensors can be implanted for up to a year. Senseonics recently reached an agreement with Ascensia to bring its commercial operations, including sales and marketing, in-house.

About 12 million people use CGMs today, just a fraction of adults globally with diabetes, according to Sava. 

“The market is growing, but with just two manufacturers leading it, demand is outpacing choice for distributors, clinicians and patients,” Sava said in a statement. 

With the recent Series B round, Sava has raised a total of $68 million to date, the company said. Other investors included Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments and Pentland Ventures.

来源:MedTech Dive 器械媒体 · medtechdive.com